MATERNUS-Kliniken AG (DE:MAK)
XETRA:MAK
Want to see DE:MAK full AI Analyst Report?
Top Page
MATERNUS-Kliniken AG
(XETRA:MAK)
Select Model
Select Model
Rating:44Neutral
Price Target:
€0.79
▼(-19.80% Downside)
Action:Reiterated
Date:06/02/26
The score is held down primarily by weak financial fundamentals—especially negative equity and high leverage alongside ongoing losses and a steep 2025 revenue drop—partly offset by currently positive operating and free cash flow. Technicals are mixed with price below key longer-term moving averages and negative MACD, while valuation is constrained by a negative P/E due to losses.
Positive Factors
Stable recurring revenue model
The core business is long-term residential senior care with recurring reimbursements and resident fees. That payer mix and contract-like revenues tend to be stable and predictable, supporting durable cash inflows and operational planning over the next 2–6 months.
Negative Factors
Negative shareholders' equity
Substantial negative equity signals an impaired capital base and materially reduces financial flexibility. Over the coming months this elevates risk around covenants, refinancing access and counterparty confidence, constraining strategic options and capital investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable recurring revenue model
The core business is long-term residential senior care with recurring reimbursements and resident fees. That payer mix and contract-like revenues tend to be stable and predictable, supporting durable cash inflows and operational planning over the next 2–6 months.
Read all positive factors
MATERNUS-Kliniken AG (MAK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€19.71M
Dividend YieldN/A
Average Volume (3M)618.00
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue Growth3.51%
EPS Growth-5.66%
CountryDE
Employees1,452
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.72
Shares Outstanding20,970,000
10 Day Avg. Volume1,293
30 Day Avg. Volume618
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)-0.27
Price to Sales (P/S)0.18
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MATERNUS-Kliniken AG Business Overview & Revenue Model
Company Description
Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medic...
How the Company Makes Money
MATERNUS-Kliniken AG primarily generates revenue by providing long-term care services within its senior-care facilities. Key revenue streams typically include recurring payments for nursing and residential care (often comprising care-related reimb...
MATERNUS-Kliniken AG Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
9
Very Negative
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.47M | 118.00M | 114.00M | 102.31M | 106.70M | 111.44M |
| Gross Profit | 45.57M | 23.00M | 98.78M | 87.45M | 86.98M | 97.52M |
| EBITDA | 8.46M | 4.08M | 10.71M | 4.71M | 1.71M | 14.96M |
| Net Income | -15.51M | -13.90M | -13.16M | -14.26M | -14.08M | -2.56M |
Balance Sheet | ||||||
| Total Assets | 137.19M | 149.87M | 139.88M | 154.38M | 153.40M | 165.41M |
| Cash, Cash Equivalents and Short-Term Investments | 2.18M | 5.35M | 4.94M | 9.99M | 5.20M | 16.02M |
| Total Debt | 186.99M | 183.19M | 165.41M | 112.35M | 117.81M | 123.65M |
| Total Liabilities | 204.59M | 230.46M | 206.72M | 206.49M | 190.95M | 186.76M |
| Stockholders Equity | -68.94M | -80.59M | -66.84M | -53.76M | -39.30M | -25.34M |
Cash Flow | ||||||
| Free Cash Flow | 9.74M | 11.16M | 13.86M | -1.44M | 2.33M | 15.32M |
| Operating Cash Flow | 9.84M | 14.03M | 15.07M | 2.52M | 4.33M | 17.24M |
| Investing Cash Flow | 48.00K | -2.87M | -1.07M | -3.96M | -2.00M | -1.92M |
| Financing Cash Flow | -11.29M | -10.17M | -11.68M | -69.00K | -12.76M | -12.79M |
MATERNUS-Kliniken AG Technical Analysis
Negative
0.98
Price Trends
1.01
Negative
1.05
Negative
1.05
Negative
Market Momentum
-0.03
Negative
47.88
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MAK, the sentiment is Negative. The current price of 0.98 is above the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.01, and below the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.88 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MAK.
MATERNUS-Kliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €157.50M | 26.05 | 24.05% | ― | 33.49% | 81.79% | |
63 Neutral | €192.85M | 7.01 | 11.90% | 1.12% | 5.13% | 11.89% | |
57 Neutral | €843.42M | 21.06 | 3.04% | 0.77% | 6.06% | 0.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | €19.71M | -1.23 | 21.40% | ― | 3.51% | -5.66% |
* Healthcare Sector Average
DE:MAK
MATERNUS-Kliniken AG
0.92
-0.54
-36.99%
DE:MED
MEDICLIN
4.00
0.93
30.42%
DE:RHK
RHON-KLINIKUM AG
12.60
0.99
8.52%
DE:LIK
Limes Schlosskliniken AG
555.00
188.12
51.28%
DE:EIF
Eifelhoehen-Klinik AG
4.02
2.53
169.80%
DE:JTH0
Gesundheitswelt Chiemgau AG
11.20
-0.49
-4.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.